Methodology: each issue's direction is a live signal — long/short opens or holds a position, neutral means flat, and every direction change opens, flips, or closes it. Returns are direction-aware (a short gains when the price falls) and compound across positions from first observation to the latest issue. "Price move" is the stock's own raw change, shown separately. Neither represents actual portfolio performance.
Brief History (4 issues)
Down 2.27% with RSI at 28.4 and RSI(7) at 14.5 in extreme oversold territory; Q2 adjusted EPS beat by 41% and full-year guidance rose to $7.90-8.10, yet the stock sold off on call commentary about 2027 Caremark membership attrition and 340B pressure — the bad news sits in the out-years, not the quarter. Thirty analysts at 22.0% upside — staying flat.
Flat, with RSI at 31.6 and RSI(7) at 18.0 deeply oversold, beneath the 20-day at $104.77 and 50-day at $101.92 but above the 200-day at $85.11; 30 analysts see $114.06, 19.2% above spot — awaiting a stabilization signal.
Down 0.54% with RSI(7) deeply oversold at 18.0 after a 9.3% week, below the 50-day at $101.87 while holding above the 200-day at $85.05; medical cost pressure is unresolved. Sidelines.
Up 1.3% into 52-week-high ground, the turnaround +31% YTD; a valid breakout with just 3% left to consensus targets